References
Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34:51–54
Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, Meru M, Palmblad J, Mauritzson N, Westin J, Samuelsson J (2004) Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89:520–527
James CW (2000) Anagrelide-induced cardiomyopathy. Pharmacotherapy 20:1224–1227
Jurgens DJ, Moreno-Aspitia A, Tefferi A (2004) Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica 89:1394–1395
Spencer CM, Brogden RN (1994) Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 47:809–822
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wong, R.S.M., Lam, L.W.K. & Cheng, G. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Ann Hematol 87, 683–684 (2008). https://doi.org/10.1007/s00277-008-0451-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0451-6